A study assessing immune‐related adverse events associated with the treatment of immune checkpoint inhibitors (ICI) for malignancies
Latest Information Update: 28 Jan 2021
At a glance
- Drugs Atezolizumab (Primary) ; Avelumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 27 Mar 2020 New trial record
- 18 Mar 2020 Results published in the Journal of Gastroenterology and Hepatology